| Q27302081 | A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen |
| Q28742853 | A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses |
| Q33745355 | A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level |
| Q33815728 | A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers |
| Q36201361 | A transcriptome-based model of central memory CD4 T cell death in HIV infection. |
| Q41031764 | Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. |
| Q44498209 | An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques |
| Q34699156 | An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers |
| Q35489088 | Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers |
| Q93196555 | Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination |
| Q90050621 | Blocking Formation of the Stable HIV Reservoir: A New Perspective for HIV-1 Cure |
| Q35653249 | Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy |
| Q46762458 | CD26: a negative selection marker for human Treg cells |
| Q36731541 | CD38 Expression in a Subset of Memory T Cells Is Independent of Cell Cycling as a Correlate of HIV Disease Progression |
| Q35599441 | CD4 T cell depletion at the cervix during HIV infection is associated with accumulation of terminally differentiated T cells. |
| Q34057778 | CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination |
| Q40233843 | CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals |
| Q38098176 | Cell-Mediated Immunity in Elite Controllers Naturally Controlling HIV Viral Load. |
| Q51009179 | Central memory CD4 cells are an early indicator of immune reconstitution in HIV/AIDS patients with anti-retroviral treatment. |
| Q38067705 | Characteristics of plasmacytoid dendritic cell and CD4+ T cell in HIV elite controllers |
| Q47619072 | DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers |
| Q37619109 | DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies |
| Q90479580 | Delineation of Homeostatic Immune Signatures Defining Viremic Non-progression in HIV-1 Infection |
| Q39097804 | Dendritic Cell Immune Responses in HIV-1 Controllers |
| Q37628515 | Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine |
| Q45074789 | Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells |
| Q42205079 | Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load |
| Q34733986 | Different immunological phenotypes associated with preserved CD4+ T cell counts in HIV-infected controllers and viremic long term non-progressors |
| Q35826902 | Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers |
| Q37077305 | Disease Progression in HIV-1-Infected Viremic Controllers |
| Q35001377 | Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? |
| Q22241984 | Emerging concepts in the immunopathogenesis of AIDS |
| Q42207149 | Epigenetic repression of interleukin 2 expression in senescent CD4+ T cells during chronic HIV type 1 infection. |
| Q37308188 | Expression profile of host restriction factors in HIV-1 elite controllers |
| Q21146758 | Generalized immune activation as a direct result of activated CD4+ T cell killing |
| Q26995220 | Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? |
| Q33535905 | HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity |
| Q41762711 | HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. |
| Q34190681 | HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses |
| Q38114915 | HIV controllers: a genetically determined or inducible phenotype? |
| Q37921949 | HIV controllers: a multifactorial phenotype of spontaneous viral suppression |
| Q89547831 | HIV-1 elite controllers present a high frequency of activated regulatory T and Th17 cells |
| Q59356430 | HIV-1 targets L-selectin for adhesion and induces its shedding for viral release |
| Q37866624 | HIV-specific CD4 T cells and immune control of viral replication |
| Q34699130 | HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers |
| Q40659603 | Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers |
| Q35344875 | Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques |
| Q34490116 | High CCR5 density on central memory CD4+ T cells in acute HIV-1 infection is mostly associated with rapid disease progression |
| Q35005192 | High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers |
| Q35751335 | Higher Frequency of NK and CD4+ T-Cells in Mucosa and Potent Cytotoxic Response in HIV Controllers |
| Q33350161 | Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression |
| Q33952015 | Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy |
| Q30424366 | Human immunodeficiency virus vaccine trials |
| Q41077589 | Identity, Representations, and Beliefs: HIV Controllers Living on the Frontier of Good Health and Illness |
| Q60961055 | Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers |
| Q34657787 | Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1. |
| Q34575451 | Immune mechanisms of HIV control |
| Q50960985 | Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. |
| Q30362489 | Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? |
| Q37643349 | Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine |
| Q40128331 | Impact of Vaccination on Distribution of T Cell Subsets in Antiretroviral-Treated HIV-Infected Children |
| Q42427922 | In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice |
| Q34633434 | Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses |
| Q30372415 | Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. |
| Q64252443 | Increased Regulatory T-Cell Activity and Enhanced T-Cell Homeostatic Signaling in Slow Progressing HIV-infected Children |
| Q42130441 | Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease |
| Q34105477 | Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals |
| Q37141704 | Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge |
| Q35956923 | Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort |
| Q64262002 | Mass cytometry identifies distinct CD4+ T cell clusters distinguishing HIV-1-infected patients according to antiretroviral therapy initiation |
| Q58604129 | Mucosal T helper 17 and T regulatory cell homeostasis correlates with acute SIV viremia and responsiveness to antiretroviral therapy in macaques |
| Q37169129 | Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control |
| Q35868009 | Plasmacytoid dendritic cells reduce HIV production in elite controllers |
| Q82964253 | Polyfunctional analysis of Gag and Nef specific CD8+ T-cell responses in HIV-1 infected Indian individuals |
| Q42267194 | Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine |
| Q37785949 | Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. |
| Q36951735 | Public T cell receptors confer high-avidity CD4 responses to HIV controllers |
| Q37867102 | Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems |
| Q28083514 | Recent developments in clinical trial designs for HIV vaccine research |
| Q36759963 | Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. |
| Q27487961 | Sang Froid in a time of trouble: is a vaccine against HIV possible? |
| Q35745365 | Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection |
| Q39845365 | Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. |
| Q38491191 | Success and failure of the cellular immune response against HIV-1. |
| Q37789345 | T cell immunity in acute HIV-1 infection. |
| Q37385041 | Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells |
| Q36060423 | The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope |
| Q27025707 | The enduring tale of T cells in HIV immunopathogenesis |
| Q34740235 | The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study |
| Q36010933 | Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors |
| Q37295142 | Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus |
| Q49545801 | α4β7+ CD4+ effector/effector memory T cells differentiate into productively and latently infected central memory T cells by TGFβ1 during HIV-1 infection. |